Friday, September 20, 2013

New treatment option: 223Ra chloride, the first approved unsealed α-emitting radiopharmaceutical Published on 29 August 2013

A 66-year-old man with prostate cancer presented with intractable pain associated with multifocal bone metastases.

After receiving 180 µCi (1.35 µCi/kg) of 223Ra chloride, radiation survey measured 0.2 mR/h at 1 m, and the patient was discharged to home. He will return monthly for the next 5 months for repeat 223Ra chloride administrations. 223Ra chloride is the first Food and Drug Administration-approved unsealed α-emitting radiopharmaceutical.



Post a Comment

Twitter Delicious Facebook Digg Stumbleupon Favorites More

Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Bluehost Review